Hikma Confirms Leadership Changes As Former CEO Returns And CFO Joins Board

Hikma Pharmaceuticals announced that Riad Mishlawi has stepped down from his role as Chief Executive Officer and resigned from the company’s Board of Directors, effective immediately, by mutual agreement. The leadership change marks a transition as the company continues to focus on executing its long-term strategic priorities.

Victoria Hull, Hikma’s Senior Independent Director said: “The Board is confident in Hikma’s future growth prospects under the experienced leadership of Said, supported by Hikma’s talented global team. We will be launching a search for a new CEO in due course.” 

Said Darwazah, Hikma’s Executive Chairman and former CEO, will assume CEO responsibilities with immediate effect, ensuring continuity in leadership. Additionally, Khalid Nabilsi, Chief Financial Officer, has been appointed to Hikma’s Board of Directors and will assume expanded management responsibilities to further reinforce the Group’s strategic execution and operational focus.

Said Darwazah said: “I would like to thank Riad for his contributions over his long career at Hikma and we wish him well for the future. I look forward to continuing to work closely with Hikma’s Executive Committee and with Khalid in his expanded role to deliver on our strategic plans.” 

Hikma reaffirmed that its 2025 financial guidance remains unchanged from the trading update issued on 6 November 2025. The company is scheduled to report its full-year 2025 results on 26 February 2026.

Riad Mishlawi said: “I’d like to thank Said and all my Hikma colleagues. It has been an honour to work alongside you and, as I move into retirement, I wish you continued growth and every success.” 

Headquartered in the UK, Hikma has established a strong global presence across North America, the Middle East and North Africa, and Europe over the past 45 years. The company continues to focus on delivering high-quality branded and non-branded generic medicines, leveraging its global scale and local expertise to improve access to essential treatments worldwide.